albuterol has been researched along with Day Blindness in 1 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current protocol for systemic reactions in immunotherapy is for the prescribing physician to reassess the dosing and schedule as well as the risk:benefit assessment for the therapy and determine whether or not to proceed." | 1.48 | Neurologic manifestations in anaphylaxis due to subcutaneous allergy immunotherapy: A case report. ( Mangold, M; Qureshi, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mangold, M | 1 |
| Qureshi, M | 1 |
1 other study available for albuterol and Day Blindness
| Article | Year |
|---|---|
Neurologic manifestations in anaphylaxis due to subcutaneous allergy immunotherapy: A case report.
Topics: Albuterol; Anaphylaxis; Anti-Allergic Agents; Bronchodilator Agents; Desensitization, Immunologic; D | 2018 |